Gilead's Quad Poised To Take Chunk Of Atripla's Market, If Phase III Results Hold Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Solid efficacy with fewer psych effects than Atripla continue in full-length version of Phase II trials. However, hopes for superior performance have started to wane.